Research in Pharmaceutical Sciences

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 14  |  Issue : 4  |  Page : 308--319

Nicotine, as a novel tolerogenic adjuvant, enhances the efficacy of immunotherapy in a mouse model of allergic asthma


Ebrahim Mazloomi1, Behrooz Ilkhanizadeh2, Ahad Zare3, Adel Mohammadzadeh4, Nowruz Delirezh5, Shahram Shahabi1 
1 Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, I.R, Iran
2 Department of Pathology, School of Medicine, Urmia University of Medical Sciences, Urmia, I.R, Iran
3 Immunology, Asthma and Allergy Research Institute, Tehran University of Medical sciences, Tehran, I.R, Iran
4 Department of Genetics and Immunology, School of Medicine, Urmia University of Medical Sciences, Urmia, I.R, Iran
5 Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, I.R, Iran

Correspondence Address:
Shahram Shahabi
Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, I.R.
Iran

An increasing trend in the incidence of allergic diseases including asthma and related morbidity and mortality is observed worldwide during the last decades. Allergen-specific immunotherapy is suggested for the treatment of some allergic diseases; nevertheless, there is always a menace of uncommon, but life-treating reactions due to increasing the administration of allergen extract doses. Hence, improving its efficacy may reduce the required doses as well as the risk of such reactions. The current study aimed at examining the effects of nicotine (NIC), as a tolerogenic adjuvant, on the improvement of immunotherapy efficacy in a mouse model of allergic asthma. BALB/c mice were sensitized using alum and ovalbumin (OVA) on the days 0 and 7. Mice received OVA either alone or together with NIC (1 or 10 mg/kg) on the days 21, 23, and 25. Then, the mice were challenged with OVA 5% using a nebulizer on the days 35, 38, and 41 and sacrificed the next day. Co-administration of OVA and NIC decreased the inflammation of the lung tissue, eosinophils count in the bronchoalveolar lavage (BAL) fluid, the serum level of OVA-specific immunoglobulin E, as well as interleukin (IL)-4 production, while increasing the population of antigen-specific regulatory T-cells (Treg cells) and transforming growth factor-β/IL-4 (TGF-β/IL-4) ratio compared to the OVA and control groups in a dose-dependent manner. Collectively, the findings suggest that administration of NIC plus the allergen increased immunotherapy efficacy through decreasing allergic inflammation and allergic responses intensity, and increasing Treg cells population.


How to cite this article:
Mazloomi E, Ilkhanizadeh B, Zare A, Mohammadzadeh A, Delirezh N, Shahabi S. Nicotine, as a novel tolerogenic adjuvant, enhances the efficacy of immunotherapy in a mouse model of allergic asthma.Res Pharma Sci 2019;14:308-319


How to cite this URL:
Mazloomi E, Ilkhanizadeh B, Zare A, Mohammadzadeh A, Delirezh N, Shahabi S. Nicotine, as a novel tolerogenic adjuvant, enhances the efficacy of immunotherapy in a mouse model of allergic asthma. Res Pharma Sci [serial online] 2019 [cited 2019 Sep 22 ];14:308-319
Available from: http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2019;volume=14;issue=4;spage=308;epage=319;aulast=Mazloomi;type=0